ACCESS Newswire
10 Jul 2025, 19:47 GMT+10
Dual siRNA Therapeutic Confirms Its Robust In Vivo Results, Strongly De-Risking the Clinical Path and Underscoring CCT-217's Potential as a Transformative, Patient-Friendly Therapy for Obesity and Metabolic Disorders
BOSTON, MASSACHUSETTS / ACCESS Newswire / July 10, 2025 / Canary Cure Therapeutics (Canary), a pioneering biopharmaceutical company, today announced groundbreaking human cell data for its lead therapeutic candidate, CCT-217. The findings confirm a unique mechanism that promotes rapid, selective fat loss while preserving and building muscle. This strong human and preclinical evidence de-risks the clinical path for a transformative, twice-yearly treatment for obesity, with Phase 1 trials targeted for 2026.
The global obesity market is projected to exceed $200 billion by 2031, yet current treatments primarily rely on appetite suppression, often leading to significant loss of healthy muscle. CCT-217 represents a paradigm shift by targeting the underlying metabolic causes of obesity.
'While weight loss can be achieved by decreasing calorie intake, we believe increasing the body's ability to burn fat - especially harmful visceral fat - is a fundamentally healthier approach,' said Raj Reddy, CEO of Canary. 'Our goal is to improve body composition and overall metabolic function.'
Developed from Canary's proprietary dual siRNA platform, CCT-217 is engineered to increase energy expenditure by converting energy-storing white fat into metabolically active, energy-burning beige fat.
Highlights From Recent Data:
Human Cell Data Confirms Mechanism: Recent studies on differentiated human white fat cells treated with CCT-217 showed a rapid and significant increase in key thermogenic gene markers within just 72 hours. This powerful result in human cells validates the therapy's core mechanism and potential efficacy, providing a clear path toward clinical trials.
Dramatic, Fat-Selective Weight Loss in Preclinical Models: In diet-induced obese (DIO) animal models, CCT-217 demonstrated remarkable results in only 20 days:
26% reduction in total body weight
60% reduction in harmful visceral fat
25% increase in lean muscle mass
Comprehensive Metabolic Health Improvements: Beyond weight loss, CCT-217 treatment led to a complete reversal of liver steatosis (fatty liver), a 20% reduction in cholesterol, and enhanced insulin sensitivity, underscoring its potential to address a wide range of obesity-related co-morbidities.
CCT-217 offers patient-friendly, twice-yearly subcutaneous injections, using a proven Lipid Nanoparticle (LNP) platform to target siRNA delivery to adipose tissue - an endocrine organ central to the development of metabolic diseases - while minimizing off-target effects. Canary's second asset, CCT-007, targets genes over-expressed in post-menopausal women for healthy weight loss with fewer side effects.
'The strong correlation between our new human cell data and the dramatic in vivo animal model outcomes provides critical de-risking evidence,' said Dr. Reddy. 'We are now focused on advancing CCT-217 into Phase 1 clinical trials in 2026 to bring this next-generation therapy to patients. We are fortunate to have exceptional advisors overseeing the clinical development including Dr. Michael Lincoff, Principal Investigator of the groundbreaking SELECT Trial.'
Canary is currently raising a Series A round of $25 million to advance CCT-217 into Phase 1 trials, expected to start in 2026.
About Canary Cure Therapeutics
Canary Cure Therapeutics is a late-stage preclinical biopharmaceutical company pioneering next-generation RNA therapeutics for obesity and metabolic disease. Its proprietary dual-siRNA platform is engineered to induce class-leading thermogenesis, offering a differentiated, muscle-sparing approach to weight loss and metabolic health.
Contact Information
Anna Wang
Chief Strategy Officer
[email protected]
+41 79 204 2875
SOURCE: Canary Cure Therapeutics
Get a daily dose of Australian Herald news through our daily email, its complimentary and keeps you fully up to date with world and business news as well.
Publish news of your business, community or sports group, personnel appointments, major event and more by submitting a news release to Australian Herald.
More InformationWASHINGTON, D.C.: An elaborate impersonation scheme involving artificial intelligence targeted senior U.S. and foreign officials in...
SLUBICE, Poland: Poland reinstated border controls with Germany and Lithuania on July 7, following Germany's earlier reintroduction...
WASHINGTON, D.C.: After months of warnings from former federal officials and weather experts, the deadly flash floods that struck the...
MOSCOW, Russia: Just hours after his sudden dismissal by President Vladimir Putin, Russia's former transport minister, Roman Starovoit,...
DHARAMSHALA, India: The Dalai Lama turned 90 on July 6, celebrated by thousands of followers in the Himalayan town of Dharamshala,...
ZAGREB, Croatia: A massive concert by popular Croatian singer Marko Perković, known by his stage name Thompson, has drawn widespread...
London [UK], July 10 (ANI): Indian head coach Gautam Gambhir spoke on his mindset as a coach, saying that for him, first-class cricket...
Bengaluru (Karnataka) [India], July 10 (ANI): Hockey India on Thursday named a 33-member core probable group for the Senior Men's National...
BEIJING, July 10 (Xinhua) -- A series of research findings by Chinese scientists on the samples collected by the Chang'e-6 mission...
Australia's drug approval system is under fire, with critics in the United States claiming it is too slow to approve life-saving medicines....
Windhoek [Namibia], July 10 (ANI): Prime Minister Narendra Modi's references to cricket during his address to the joint session of...
London [UK], July 9 (ANI): England captain Ben Stokes is not dwelling on past achievements as he prepares to lead his side into the...